Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B.
Yanhua TangRong FanZhixian LanQing XieJiping ZhangXieer LiangHao WangDeming TanJun ChengShijun ChenQin NingXuefan BaiMin XuXinyue ChenJunqi NiuJunping ShiHong RenZhiliang GaoMaorong WangXiaoguang DouJinlin HouJian SunPublished in: Journal of medical virology (2023)
In HBeAg-positive CHB patients receiving NAs therapy, new-onset and sustained NAFLD may counteract the benefits of antiviral therapy, reducing the rate of biochemical response and fibrosis improvement. This article is protected by copyright. All rights reserved.